

MAR 7 2002

## Section 3

**510(k) SUMMARY OF SAFETY AND EFFECTIVENESS**

IMUBIND® Plasma PAI-1 ELISA

Quantitative Factor Deficiency Test (per 21CFR864.7290)

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K013168

**Submitted by:**

American Diagnostica Inc.

222 Railroad Avenue

Greenwich, CT 06830

Phone: 203 661-0000

Fax: 203 661-7784

**Contact:**

Clare Santulli

Field Trial Coordinator

Phone: 203 661-0000

**Summary Prepared:**

August 12, 2001

**Name of the Device:**

IMUBIND® Plasma PAI-1 ELISA

Product No. 822

**Classification Name(s):**

864.7290 Test, Quantitative Factor Deficiency

GGP Hematology, Class II

**Predicate Device:**

K960438 BIOPOOL TintElize® PAI-1

**Intended Use:**

The IMUBIND® Plasma PAI-1 ELISA is an enzyme-linked immunosorbent assay for the measurement of Plasminogen Activator Inhibitor Type-1 (PAI-1) antigen in human plasma.

### Summary of Substantial Equivalence:

IMUBIND Plasma PAI-1 ELISA is substantially equivalent to the commercially available predicate device (TintElize PAI-1, manufactured by Biopool International, Ventura, CA) in performance and intended use.

### Summary of Performance Data:

#### Method Comparison

Method comparison studies versus the predicate device were performed with one lot of IMUBIND Plasma PAI-1 ELISA. The regression statistics in Table 1 indicate a positive correlation between the IMUBIND assay and the predicate device.

**Table 1:** Correlation (Y=IMUBIND, X=predicate device)

IMUBIND Plasma PAI-1	N	Regression Equation	R	Sy.x (ng/ml)	Sample Range (ng/ml)
1	247	$Y=1.01X+1.3$	0.94	4.42	0.2-49.8

#### Precision

Precision studies evaluated intra-assay and inter-assay variability with 2 control samples run in replicates of 4 over 10 runs (N=40 per control). Two lots were evaluated.

**Table 2:** Precision

IMUBIND Plasma PAI-1	Mean (ng/ml)	Intra-Assay CV%	Inter-Assay CV%
Lot 1	11.5	5.7	5.1
	40.9	4.1	2.1
Lot 2	11.3	5.7	4.7
	40.3	4.2	4.7

## Section 4

**SUBSTANTIAL EQUIVALENCE COMPARISON**

A comparison table of the relevant similarities and differences between IMUBIND Plasma PAI-1 ELISA and the predicate device:

	<b>IMUBIND Plasma PAI-1 ELISA</b>	<b>TintElize PAI-1</b>
Intended Use	Similar	Similar
Principle and Method	All plate wells contain antibody to PAI-1	Half of the plate wells contain antibody (A-well) to PAI-1, half of the plate wells contain no antibody (N-well) providing a blank to be subtracted from the absorbance value for each sample
Reagents	Similar	Similar
Storage and Stability	Similar	Similar
Specimen	Similar	Similar
Limitations	Similar	Similar
Expected Values	Similar	Similar
Performance Characteristics	Similar	Similar

Similar performance and values were obtained with both devices suggesting that the method difference does not affect device equivalence.

IMUBIND Plasma PAI-1 ELISA is substantially equivalent to the commercially available predicate device (TintElize PAI-1, manufactured by Biopool International, Ventura, CA) in method, performance and intended use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

MAR 7 2002

Mr. John Berryman  
Director of Regulatory Affairs  
American Diagnostica Inc.  
222 Railroad Avenue  
Greenwich, CT 06830

Re: k013168  
Trade/Device Name: IMUBIND® Plasma PAI-1 ELISA  
Regulation Number: 21 CFR 864.7290  
Regulation Name: Factor deficiency test  
Regulatory Class: Class II  
Product Code: GGP  
Dated: January 8, 2002  
Received: January 10, 2002

Dear Mr. Berryman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory-Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Section 2

**STATEMENT OF INDICATIONS FOR USE**Applicant: American Diagnostica Inc.510(k) Number: K013168Device: IMUBIND® Plasma PAI-1 ELISA**Indications for Use:**


The IMUBIND® Plasma PAI-1 ELISA is an enzyme-linked immunosorbent assay for the measurement of human Plasminogen Activator Inhibitor Type-1 (PAI-1) antigen in plasma.

This kit is for *in vitro* diagnostic use.

High levels of PAI-1 antigen are known to be associated with deep vein thrombosis and myocardial infarction.

---

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K013168